Polypharmacology

Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024

Retrieved on: 
Friday, April 12, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, American Academy, Immunoglobulin G, BCR, Tissue, Proteinuria, CDC, Novel, Myasthenia gravis, Doctor of Philosophy, Pharmacology, ADCC, Patient, Blood urea nitrogen, AAN, Polypharmacology, Autoimmunity, Vaccine

Seismic Therapeutic, Inc ., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver.

Key Points: 
  • Seismic Therapeutic, Inc ., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver.
  • The poster presentation titled, “Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases,” features preclinical in vitro and in vivo results supporting the differentiated therapeutic profile of S-1117.
  • S-1117 reduced IgG effector functions, significantly reducing antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of peripheral blood mononuclear cells (PBMCs).
  • A murine nephritis model showed reduced complement and immune complex deposition, as well as reduced proteinuria, blood urea nitrogen and renal pathology.

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

Retrieved on: 
Monday, April 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Entrepreneurship, Drug discovery, Patient, NEK1, Biology, Computational chemistry, Harmonic, Therapy, Multimedia, Polypharmacology

Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Key Points: 
  • Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240401176466/en/
    “We believe that the dark kinase NEK1 holds great potential as a drug target for developing cancer therapies addressing important resistance challenges in the clinic,” said Daniel Veres, M.D., Ph.D., Chief Scientific Officer and Co-Founder of Turbine.
  • Harmonic will assume responsibilities for computational chemistry and medicinal chemistry activities, while Turbine will be responsible for in silico simulations and wet-lab validation of target biology, including the identification of both synergistic kinase co-targets to NEK1 and patient populations most likely to benefit from therapies.

Groundbreaking Study Finds Natural Formulation by MDbio – The Doctors BrandTM Significantly Improves Sleep, Anxiety, Stress, and Overall Well-being

Retrieved on: 
Tuesday, October 3, 2023
Volunteering, GABA, Theanine, Doctor of Pharmacy, Melatonin, University, Doctor, Anxiety, Sleep, Clinical trial, Public, Cannabinoid, Research, Harvard University, Maryland School, MCID, CBN, Harvard T.H. Chan School of Public Health, Public health, MD, Polypharmacology, University of Maryland School of Medicine, CBD, FACS, Faculty, Entrepreneurship, UCLA, THC, Pharmaceutical industry, Dietary supplement, Medicinal plants, Nutrient

Los Angeles, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- In a momentous large-scale clinical trial, a MDSleep formulation by MDbio – The Doctors BrandTM was proven to significantly improve sleep compared to placebo.

Key Points: 
  • Los Angeles, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- In a momentous large-scale clinical trial, a MDSleep formulation by MDbio – The Doctors BrandTM was proven to significantly improve sleep compared to placebo.
  • Results showed the formulation enhanced sleep onset, and supported restful and healthy sleep.
  • Furthermore, the product led to significant improvements in feelings of anxiety, stress, and well-being compared to placebo.
  • This study was one of history’s largest double-blind randomized placebo controlled trials to demonstrate effectiveness of a non-melatonin supplement for improving sleep.

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

Retrieved on: 
Monday, May 8, 2023
Acceleration, Learning, Deep learning, Intelligence, Proteome, Research, History, SALT, Drug design, Acquisition, Patient, Machine learning, Map, Polypharmacology, Algorithm, Drug discovery, Biology, Entrepreneurship, AI, Health, Pharmaceutical industry, Medical device, Cyclica, Recursion

“Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology to discover new medicines faster.

Key Points: 
  • “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology to discover new medicines faster.
  • “Cyclica and Recursion both believe in the value of industrializing drug discovery,” said Naheed Kurji, CEO and Co-Founder of Cyclica.
  • In certain limited circumstances, Recursion may pay nominal cash consideration to Valence and Cyclica shareholders in lieu of such exchangeable shares or Recursion Class A common stock.
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

Computer-Aided Drug Discovery Global Market Report 2022: Artificial Intelligence and Big Data to Reshape Sector Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Health Technology, Pharmaceutical, Health, United Nations, CVD, AstraZeneca, Charles River Laboratories, Drug design, Prevalence, AMRI, Artificial intelligence, Premier, Inc., WHO, Cardiovascular disease, Neurology, Conditional sentence, Respiratory disease, Research, World, Patient, CAGR, Diabetes, Laboratory, Biotechnology, First Nations in Ontario, COVID-19, Intelligence, Polypharmacology, UN, Bayer, Drug discovery, World Health Organization, Public health, Medical device, Pharmaceutical industry, Fine chemical

Also, lower product penetration in the emerging economies is also restraining the global computer-aided drug discovery market.

Key Points: 
  • Also, lower product penetration in the emerging economies is also restraining the global computer-aided drug discovery market.
  • Emerging concepts such as artificial intelligence (AI) and big data in computer-aided drug discovery, on the other hand, may drive the market over the forecast period.
  • Many aspects of drug discovery can benefit from artificial intelligence, including drug design, chemical synthesis, drug screening, drug repurposing, and polypharmacology.
  • The global computer-aided drug discovery market is segmented on the basis of type, therapeutic area, end-user, and region.

HARMONIC DISCOVERY LAUNCHES WITH $8 MILLION IN SEED TO DEVELOP A NEW GENERATION OF MULTI-TARGET KINASE INHIBITORS

Retrieved on: 
Thursday, September 8, 2022
Machine learning, University, Icahn School of Medicine at Mount Sinai, CEO, Cancer, Lymphatic system, DRS, Y Combinator, Astra, Agriculture, Degenerative disease, Tempus, Doctor of Philosophy, Systems biology, Entrepreneurship, Polypharmacology, Textile, University of Oslo, Board, Memorial Sloan Kettering Cancer Center, Associate, Mount Sinai, Innovation, Investment, CSO, NEW, Eric Schmidt, MD, Computational biology, Company, Therapy, Coronavirus Scientific Advisory Board (Turkey), New Board, Human Genome Sciences, SoFi, Replica, Industry, Incubator, Harmonic, Transport, Cheminformatics, Disease, Pharmaceutical industry, Formlabs, Genetics, Color

NEW YORK, Sept. 8, 2022 /PRNewswire/ -- Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, announces its launch today with $8 million in seed funding. The round was led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital and select angel investors. Dr. Joel Dudley, PhD, Partner at Innovation Endeavors, joins as a new Board Member.

Key Points: 
  • Yet, the pharmaceutical industry has historically focused on finding "magic bullets", or drugs optimized to engage specific single targets.
  • Harmonic Discovery's fully integrated kinase drug discovery platform aims to challenge this paradigm.
  • Co-founders Rayees Rahman, PhD, Jason Lee, MD, and Marcel Patek, PhD are building a machine learning-first infrastructure that integrates several aspects of kinase drug discovery.
  • Harmonic Discovery is a resident of JLABS @ NYC, part of Johnson & Johnson Innovation's global network of life science incubators.

Global Computer-aided Drug Discovery Market Anticipated to Garner a Revenue of $7,504.7 Million and Rise at a Noteworthy CAGR of 11.48% over the 2022-2030 Timeframe [240-Pages] | Research Dive

Retrieved on: 
Tuesday, June 21, 2022
Sequence, CAGR, Oncology, NEW, Intelligence, Research, Neurology, Cardiovascular disease, Cancer, Table, Hospital, Drug design, Growth, Biotechnology, Drug discovery, Computer, Diabetes, Industry, TOC, Coronavirus, Respiratory disease, Center for Urban and Regional Analysis, Polypharmacology, Drug, Pharmaceutical industry, Fine chemical

NEW YORK, June 21, 2022 /PRNewswire/ -- Research Dive has added a new report to its offering titled, 'Computer-aided Drug Discovery Market by Type (Structure-Based Drug Design (SBDD), Ligand-based Drug Design (LBDD), and Sequence-based Approaches), Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, and Others), End-user (Pharmaceutical Companies, Biotechnology Companies, and Research Laboratories) and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022–2030.'

Key Points: 
  • The global computer-aided drug discovery market is expected to see striking growth by 2030, due to the growing utilization of artificial intelligence in drug discovery.
  • According to the report published by Research Dive, the global computer-aided drug discovery market is anticipated to generate a revenue of $7,504.7 million and grow at a healthy CAGR of 11.48% during the estimated period from 2022 to 2030.
  • However, the lack of skilled professionals in this field may hinder the growth of the market over the estimated timeframe.
  • Though the rise of the novel coronavirus has devastated several other industries, the computer-aided drug discovery market has experienced a positive impact during the pandemic period.

Global Computer-aided Drug Discovery Market Anticipated to Garner a Revenue of $7,504.7 Million and Rise at a Noteworthy CAGR of 11.48% over the 2022-2030 Timeframe [240-Pages] | Research Dive

Retrieved on: 
Tuesday, June 21, 2022
Sequence, CAGR, Oncology, NEW, Intelligence, Research, Neurology, Cardiovascular disease, Cancer, Table, Hospital, Drug design, Growth, Biotechnology, Drug discovery, Computer, Diabetes, Industry, TOC, Coronavirus, Respiratory disease, Center for Urban and Regional Analysis, Polypharmacology, Drug, Pharmaceutical industry, Fine chemical

NEW YORK, June 21, 2022 /PRNewswire/ -- Research Dive has added a new report to its offering titled, 'Computer-aided Drug Discovery Market by Type (Structure-Based Drug Design (SBDD), Ligand-based Drug Design (LBDD), and Sequence-based Approaches), Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, and Others), End-user (Pharmaceutical Companies, Biotechnology Companies, and Research Laboratories) and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022–2030.'

Key Points: 
  • The global computer-aided drug discovery market is expected to see striking growth by 2030, due to the growing utilization of artificial intelligence in drug discovery.
  • According to the report published by Research Dive, the global computer-aided drug discovery market is anticipated to generate a revenue of $7,504.7 million and grow at a healthy CAGR of 11.48% during the estimated period from 2022 to 2030.
  • However, the lack of skilled professionals in this field may hinder the growth of the market over the estimated timeframe.
  • Though the rise of the novel coronavirus has devastated several other industries, the computer-aided drug discovery market has experienced a positive impact during the pandemic period.

Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease

Retrieved on: 
Wednesday, March 23, 2022
Oncology, Mental Health, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Disease, Polypharmacology, Neurodegeneration, Inc., Machine learning, Neurology, Automation, Multimedia, Research, CEO, Entrepreneurship, MD, Alzheimer's disease, Drug discovery, Assay, Patient, Partnership, Pharmaceutical industry, Fine chemical, CYCLICA, ARCTORIS

Cyclica Inc. (Cyclica), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (Arctoris), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimers disease.

Key Points: 
  • Cyclica Inc. (Cyclica), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (Arctoris), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimers disease.
  • Dr. Martin-Immanuel Bittner, MD DPhil FRSA, CEO of Arctoris, comments by sharing, Our joint drug discovery program focuses on dual specificity inhibitors - a very promising yet also challenging modality.
  • Cyclica and Arctoris have long-term plans for their partnership as discussions are already underway about tackling additional therapeutic targets.
  • This press release contains forward-looking statements and forward-looking information which include, among other things, plans to advance drug discovery programs by Cyclica and Arctoris.

Herophilus Appoints Brad Savall, Ph.D. as Vice President and Head of Chemistry as it Advances Pipeline of Novel Drugs for Complex Brain Diseases

Retrieved on: 
Tuesday, January 25, 2022
Biotechnology, Pharmaceutical, Health, Mental Health, Disorder, Lists of diseases, Psychiatry, Sanford Burnham Prebys Medical Discovery Institute, Associate, Biotechnology, Brain, Multimedia, Coronavirus Scientific Advisory Board (Turkey), Neurological disorder, Medicinal chemistry, Drug discovery, Organoid, Machine learning, Polypharmacology, Neurodegeneration, CEO, Pharmaceutical industry, Management, Herophilos, Chemistry

Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, today announced the appointment of Brad Savall, Ph.D. as the companys new Vice President and Head of Chemistry.

Key Points: 
  • Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, today announced the appointment of Brad Savall, Ph.D. as the companys new Vice President and Head of Chemistry.
  • Dr. Savall brings to Herophilus over 20 years of experience in medicinal chemistry, including the design of molecules optimized for brain diseases, as the company continues to progress their pipeline of novel drugs for neurological and psychiatric disease.
  • In contrast to traditional single target-focused drug discovery, Herophiluss technology yields robust drug candidates, identifies polypharmacologic drugs and combination therapies, and ultimately enables systematic drug discovery for complex brain diseases.
  • Herophilus is a San Francisco-based neurotherapeutics company focused on curing complex brain diseases.